AAAAAA
Results:
1-14
|
Results: 14
Authors:
DAMSBO P
HERMANN LS
VAAG A
HOTHERNIELSEN O
BECKNIELSEN H
Citation: P. Damsbo et al., IRREVERSIBILITY OF THE DEFECT IN GLYCOGEN-SYNTHASE ACTIVITY IN SKELETAL-MUSCLE FROM OBESE PATIENTS WITH NIDDM TREATED WITH DIET AND METFORMIN, Diabetes care, 21(9), 1998, pp. 1489-1494
Authors:
GOLDBERG RB
EINHORN D
LUCAS CF
RENDELL MS
DAMSBO P
HUANG WC
STRANGE P
BRODOWS RG
Citation: Rb. Goldberg et al., A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF REPAGLINIDE IN THE TREATMENTOF TYPE-2 DIABETES, Diabetes care, 21(11), 1998, pp. 1897-1903
Authors:
MARBURY TC
HATORP V
DAMSBO P
MULLER PG
Citation: Tc. Marbury et al., REPAGLINIDE CAN BE GIVEN IN A FLEXIBLE PREPRANDIAL DOSING REGIMEN IN PATIENTS WITH TYPE-2 DIABETES, Diabetologia, 41, 1998, pp. 913-913
Authors:
GOLDBERG RB
BRODOWS RG
DAMSBO P
Citation: Rb. Goldberg et al., A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF REPAGLINIDE IN THE TREATMENT OF TYPE-2 DIABETES, Diabetes, 47, 1998, pp. 383-383
Authors:
MARBURY TC
HATORP V
DAMSBO P
MULLER PG
Citation: Tc. Marbury et al., REPAGLINIDE CAN BE GIVEN IN A FLEXIBLE PREPRANDIAL DOSING REGIMEN IN PATIENTS WITH TYPE-2 DIABETES, Diabetes, 47, 1998, pp. 1373-1373
Authors:
DAMSBO P
ANDERSEN PH
LUND S
PORKSEN N
Citation: P. Damsbo et al., IMPROVED GLYCEMIC CONTROL WITH REPAGLINIDE IN NIDDM WITH 3 TIMES DAILY MEAL RELATED DOSING, Diabetes, 46, 1997, pp. 132-132
Authors:
LARSEN J
DAMSBO P
Citation: J. Larsen et P. Damsbo, GLP-1 MUST BE PRESENT CONTINUOUSLY IN ORDER TO OBTAIN A GOOD GLYCEMICCONTROL IN NIDDM, Diabetes, 46, 1997, pp. 716-716
Authors:
BECH K
DAMSBO P
ELDRUP E
BECKNIELSEN H
RODER ME
HARTLING SG
VOLUND A
MADSBAD S
Citation: K. Bech et al., BETA-CELL FUNCTION AND GLUCOSE AND LIPID OXIDATION IN GRAVES-DISEASE, Clinical endocrinology, 44(1), 1996, pp. 59-66
Authors:
LARSEN J
JALLAD N
DAMSBO P
Citation: J. Larsen et al., ONE-WEEK CONTINUOUS-INFUSION OF GLP-1(7-37) IMPROVES THE GLYCEMIC CONTROL IN NIDDM, Diabetes, 45, 1996, pp. 860-860
Authors:
VANGAAL LF
VANACKER KL
DAMSBO P
DELEEUW IH
Citation: Lf. Vangaal et al., METABOLIC EFFECTS OF REPAGLINIDE, A NEW ORAL HYPOGLYCEMIC AGENT IN THERAPY-NAIVE TYPE-2 DIABETICS, Diabetologia, 38, 1995, pp. 43-43
Authors:
TRONIER B
MARBURY TC
DAMSBO P
Citation: B. Tronier et al., A NEW ORAL HYPOGLYCEMIC AGENT, REPAGLINIDE MINIMIZES RISK OF HYPOGLYCEMIA IN WELL-CONTROLLED NIDDM PATIENTS, Diabetologia, 38, 1995, pp. 195-195
Authors:
TRONIER B
MARBURY TC
DAMSBO P
WINDFELD K
Citation: B. Tronier et al., A NEW ORAL HYPOGLYCEMIC AGENT, REPAGLINIDE MINIMIZES RISK OF HYPOGLYCEMIA IN WELL-CONTROLLED TYPE-2 DIABETIC-PATIENTS, Diabetes, 44, 1995, pp. 70-70
Authors:
JOSEFSEN K
NIELSEN H
LORENTZEN S
DAMSBO P
BUSCHARD K
Citation: K. Josefsen et al., CIRCULATING MONOCYTES ARE ACTIVATED IN NEWLY-DIAGNOSED TYPE-1 DIABETES-MELLITUS PATIENTS, Clinical and experimental immunology, 98(3), 1994, pp. 489-493
Authors:
JOSEFSEN K
NIELSEN H
LORENTZEN S
DAMSBO P
BUSCHARD K
Citation: K. Josefsen et al., MONOCYTE FUNCTIONS IN NEWLY-DIAGNOSED TYPE-1 DIABETES-MELLITUS PATIENTS, Diabetologia, 36, 1993, pp. 10000093-10000093
Risultati:
1-14
|